JP2021500336A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500336A5
JP2021500336A5 JP2020521860A JP2020521860A JP2021500336A5 JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5 JP 2020521860 A JP2020521860 A JP 2020521860A JP 2020521860 A JP2020521860 A JP 2020521860A JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5
Authority
JP
Japan
Prior art keywords
antibody
dose
subject
combination according
hu5f9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020521860A
Other languages
English (en)
Japanese (ja)
Other versions
JP7308190B2 (ja
JP2021500336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056442 external-priority patent/WO2019079549A1/en
Publication of JP2021500336A publication Critical patent/JP2021500336A/ja
Publication of JP2021500336A5 publication Critical patent/JP2021500336A5/ja
Priority to JP2022186496A priority Critical patent/JP7474827B2/ja
Application granted granted Critical
Publication of JP7308190B2 publication Critical patent/JP7308190B2/ja
Priority to JP2024003136A priority patent/JP2024024121A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020521860A 2017-10-18 2018-10-18 抗cd47及び抗pd-l1による卵巣癌の処置 Active JP7308190B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186496A JP7474827B2 (ja) 2017-10-18 2022-11-22 抗cd47及び抗pd-l1による卵巣癌の処置
JP2024003136A JP2024024121A (ja) 2017-10-18 2024-01-12 抗cd47及び抗pd-l1による卵巣癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
US62/574,073 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186496A Division JP7474827B2 (ja) 2017-10-18 2022-11-22 抗cd47及び抗pd-l1による卵巣癌の処置

Publications (3)

Publication Number Publication Date
JP2021500336A JP2021500336A (ja) 2021-01-07
JP2021500336A5 true JP2021500336A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7308190B2 JP7308190B2 (ja) 2023-07-13

Family

ID=64402251

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020521860A Active JP7308190B2 (ja) 2017-10-18 2018-10-18 抗cd47及び抗pd-l1による卵巣癌の処置
JP2022186496A Active JP7474827B2 (ja) 2017-10-18 2022-11-22 抗cd47及び抗pd-l1による卵巣癌の処置
JP2024003136A Withdrawn JP2024024121A (ja) 2017-10-18 2024-01-12 抗cd47及び抗pd-l1による卵巣癌の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186496A Active JP7474827B2 (ja) 2017-10-18 2022-11-22 抗cd47及び抗pd-l1による卵巣癌の処置
JP2024003136A Withdrawn JP2024024121A (ja) 2017-10-18 2024-01-12 抗cd47及び抗pd-l1による卵巣癌の処置

Country Status (12)

Country Link
US (1) US20210047416A1 (cg-RX-API-DMAC7.html)
EP (2) EP4194470A1 (cg-RX-API-DMAC7.html)
JP (3) JP7308190B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200070341A (cg-RX-API-DMAC7.html)
CN (1) CN111315783A (cg-RX-API-DMAC7.html)
AU (1) AU2018351007B2 (cg-RX-API-DMAC7.html)
CA (1) CA3078430A1 (cg-RX-API-DMAC7.html)
ES (1) ES2938652T3 (cg-RX-API-DMAC7.html)
PL (1) PL3697819T3 (cg-RX-API-DMAC7.html)
PT (1) PT3697819T (cg-RX-API-DMAC7.html)
SI (1) SI3697819T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019079549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
CN113825774B (zh) * 2019-05-17 2024-07-30 南京金斯瑞生物科技有限公司 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
WO2021170082A1 (zh) * 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
KR20230129482A (ko) * 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 항pd-l1/항cd47 천연항체 구조 형태의 헤테로다이머이중특이성 항체 및 그 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
CN105189556A (zh) 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
PL3204018T3 (pl) * 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CN116425875A (zh) * 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
WO2017117196A1 (en) * 2015-12-28 2017-07-06 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
AU2017210224B2 (en) * 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Similar Documents

Publication Publication Date Title
KR102329584B1 (ko) 종양 치료용 항-b7-h1 항체
JP2021500349A5 (cg-RX-API-DMAC7.html)
TW202529804A (zh) 用於癌症治療的組合療法
JP2009539841A (ja) 自己免疫疾患の治療における抗cd3抗体の投与
TW201731527A (zh) 使用抗pd-1抗體與抗clta-4抗體之組合以治療肺癌
US20260109766A1 (en) Lag-3 antagonist therapy for melanoma
JP2022531408A5 (cg-RX-API-DMAC7.html)
WO2021250533A1 (en) Methods of treatment using omalizumab or ligelizumab
WO2023147371A1 (en) Combination therapy for hepatocellular carcinoma
EP3706778A1 (en) Methods of treating a tumor
CN116600788B (zh) 盐酸米托蒽醌脂质体的用途
Kogure et al. A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: study protocol
US20240425577A1 (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
CN120456895A (zh) 使用结合egfr的抗体与细胞毒性药物的组合的癌症治疗
TW202228772A (zh) 藉由併用阿替利珠單抗、托珠單抗、吉西他濱、白蛋白結合紫杉醇之4劑的胰臟癌治療劑
EP4595980A1 (en) Method for treating membranous nephropathy with taci-fc fusion protein
US20250332252A1 (en) Antibody compositions and methods of use thereof
WO2023164662A1 (en) Treatment of squamous non small cell lung cancer
WO2024099387A1 (zh) 通过施用配体-药物偶联体治疗癌症
Dai et al. CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
WO2024193675A1 (zh) 通过施用配体-药物偶联体治疗卵巢癌
CN119630418A (zh) 抗GARP-TGF-β1/PD-1组合疗法
CN121003695A (zh) 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
HK1224560A1 (en) Anti-b7-h1 antibodies for treating tumors